PEPTIDE Registry

Reported experiences and published evidence, kept separate. Explore what people seek, what sources actually study and what remains unknown.

Collection closed. No participant results published.

What would you like to explore?

All groups and topics

Reported-use topics, not evidence grades or diagnoses. The catalog does not cover every possible experience.

Bremelanotide / PT-141

Editorial context from existing sources; independent scientific review pending. Numerical findings held. A reported-use topic does not establish direct evidence for that aim.

The US Vyleesi label concerns a specific form of acquired generalized low desire in premenopausal women. That is not approval for men or every sexual complaint.

Blood-pressure effects and labeled cardiovascular restrictions are material. A positive result for the authorized product does not establish a community stack or another preparation.

Sources and proposed-mechanism explanation

Melanocortin signaling is offered as the explanation. Desire, arousal and performance are distinct endpoints, not a single universal response.

Vyleesi prescribing information (new tab)

Practice & Evidence: claims and limits

Collection, review and methods

8 documents · 24 educational profiles · 10 guides. Hosting authorization and reviews remain pending. Drafts are not reports; they do not establish effectiveness or safety.

Methods, consent and privacy

Understanding community practices What each evidence label means Stacks, mixtures and claims of synergy How we handle reported doses and cycles Reading a peptide quality report When someone says it worked Source errors, corrections and retractions From experience to a research question The proposed Community Observation Program Reading future observational results